Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant vs Capecitabine with Pyrotinib in HR+/HER2+ MBC
NCT04646759Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Progression free survival at 24 months and Incidence of grade 3 hand foot syndrome at 1 year. Started Oct 2020; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04646759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646759.